Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
The review found no eligible studies for this question.
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).
Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
The review found no eligible studies for this question.
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).